AIM IMMUNOTECH INC. Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss
AIM IMMUNOTECH INC. (AIM) reported Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss of -$56.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2026-03-27
- AIM IMMUNOTECH INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-12-31 was -$129.00K.
- AIM IMMUNOTECH INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-09-30 was -$12.00K, a 103.61% decline year-over-year.
- AIM IMMUNOTECH INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-06-30 was $1.00K.
- AIM IMMUNOTECH INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-03-31 was -$69.00K.
- AIM IMMUNOTECH INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2025 was -$56.00K.
- AIM IMMUNOTECH INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2024 was -$663.00K.
- AIM IMMUNOTECH INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2023 was -$200.00K.
| Period end | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | -$129.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$141.00K derived: sum of 2 quarters · filed 2026-03-27 | -$140.00K derived: sum of 3 quarters · filed 2026-03-27 | -$56.00K 10-K · filed 2026-03-27 | |
| 2025-09-30 | -$12.00K 10-Q · filed 2025-11-17 | -$11.00K derived: sum of 2 quarters · filed 2025-11-17 | $73.00K 10-Q · filed 2025-11-17 | -$1.12M derived: sum of 4 quarters · filed 2026-03-27 | |
| 2025-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$68.00K 10-Q · filed 2025-08-14 | -$1.10M derived: sum of 3 quarters · filed 2026-03-27 | -$772.00K derived: sum of 4 quarters · filed 2026-03-27 | |
| 2025-03-31 | -$69.00K 10-Q · filed 2025-05-15 | -$1.10M derived: sum of 2 quarters · filed 2026-03-27 | -$773.00K derived: sum of 3 quarters · filed 2026-03-27 | -$972.00K derived: sum of 4 quarters · filed 2026-03-27 | |
| 2024-12-31 | -$1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$704.00K derived: sum of 2 quarters · filed 2026-03-27 | -$903.00K derived: sum of 3 quarters · filed 2026-03-27 | -$663.00K 10-K · filed 2026-03-27 | -$93.00K 10-K · filed 2025-03-27 |
| 2024-09-30 | $332.00K 10-Q · filed 2025-11-17 | $133.00K derived: sum of 2 quarters · filed 2025-11-17 | $373.00K 10-Q · filed 2025-11-17 | ||
| 2024-06-30 | -$199.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$219.00K 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | -$20.00K 10-Q · filed 2025-05-15 | ||||
| 2023-12-31 | -$200.00K 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |